new_0222_0301|OLMA|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0301|OLMA|1|Olema Pharmaceuticals inc Total Current Assets (Quarterly) (USD)|Olema Pharmaceuticals inc Cash and Short Term Investments (Quarterly) (USD)|Olema Pharmaceuticals inc Inventories (Quarterly) (USD)|Olema Pharmaceuticals inc Net PP&E (Quarterly) (USD)|Olema Pharmaceuticals inc Goodwill and Intangibles (Quarterly) (USD)|Olema Pharmaceuticals inc Total Liabilities (Quarterly) (USD)|Olema Pharmaceuticals inc Total Current Liabilities (Quarterly) (USD)|Olema Pharmaceuticals inc Total Long Term Liabilities (Quarterly) (USD)|Olema Pharmaceuticals inc Total Deposits (Quarterly) (USD)|Olema Pharmaceuticals inc Book Value (Quarterly) (USD)|Olema Pharmaceuticals inc Retained Earnings (Quarterly) (USD)|Olema Pharmaceuticals inc Treasury Stock (Quarterly) (USD)|Olema Pharmaceuticals inc EV to Revenues|Olema Pharmaceuticals inc EV to Earnings|Olema Pharmaceuticals inc EV to Free Cash Flow|Olema Pharmaceuticals inc EV to Assets (Quarterly)|Olema Pharmaceuticals inc PS Ratio|Olema Pharmaceuticals inc PE Ratio|Olema Pharmaceuticals inc Price to Book Value|Olema Pharmaceuticals inc PEG Ratio|Olema Pharmaceuticals inc Debt to Equity Ratio|Olema Pharmaceuticals inc Dividend Yield|Olema Pharmaceuticals inc Shareholder Yield (TTM)|Olema Pharmaceuticals inc Percent of Shares Outstanding Short|Olema Pharmaceuticals inc Total Receivables (Quarterly) (USD)|Olema Pharmaceuticals inc Total Payables (Quarterly) (USD)|Olema Pharmaceuticals inc Total Capital Stock (Quarterly) (USD)|Olema Pharmaceuticals inc Return on Invested Capital|Olema Pharmaceuticals inc Quality Ratio Score|Olema Pharmaceuticals inc Momentum Score|Olema Pharmaceuticals inc Beta (1Y)|Olema Pharmaceuticals inc Sustainable Growth Rate (TTM)|Olema Pharmaceuticals inc Institutional Investor Ownership Percentage|Olema Pharmaceuticals inc Average Diluted Shares Outstanding (Quarterly)|Olema Pharmaceuticals inc Total Employees (Annual)|Olema Pharmaceuticals inc EPS Diluted (Quarterly) (USD)|Olema Pharmaceuticals inc SG&A Expense (Quarterly) (USD)|Olema Pharmaceuticals inc Shares Outstanding|Olema Pharmaceuticals inc Repurchase of Capital Stock (Quarterly) (USD)|Olema Pharmaceuticals inc Ordinary Shares Number (Quarterly)|Olema Pharmaceuticals inc Payout Ratio|Olema Pharmaceuticals inc Quick Ratio (Quarterly)|Olema Pharmaceuticals inc Normalized Diluted EPS (Quarterly) (USD)|Olema Pharmaceuticals inc Stock Buybacks (Quarterly) (USD)|Olema Pharmaceuticals inc Effective Tax Rate (TTM)|Olema Pharmaceuticals inc Return on Equity|Olema Pharmaceuticals inc Net Income (TTM) (USD)|Olema Pharmaceuticals inc Revenue (TTM) (USD)|Olema Pharmaceuticals inc Dividend Per Share (Quarterly) (USD)|Olema Pharmaceuticals inc Revenue (Quarterly) (USD)|Olema Pharmaceuticals inc Gross Profit (Quarterly) (USD)|Olema Pharmaceuticals inc Pre-Tax Income (Quarterly) (USD)|Olema Pharmaceuticals inc Net Income (Quarterly) (USD)|Olema Pharmaceuticals inc Net Interest Income (Quarterly) (USD)|Olema Pharmaceuticals inc Price (USD)|Olema Pharmaceuticals inc Total Return Price (USD)|Olema Pharmaceuticals inc Enterprise Value (USD)|Olema Pharmaceuticals inc 30-Day Average Daily Volume|Olema Pharmaceuticals inc 1 Year Price Returns (Daily)|Olema Pharmaceuticals inc Short Interest|Olema Pharmaceuticals inc PE Ratio (Forward)|Olema Pharmaceuticals inc PE Ratio (Forward 1y)|Olema Pharmaceuticals inc PS Ratio (Forward)|Olema Pharmaceuticals inc PS Ratio (Forward 1y)|Olema Pharmaceuticals inc Quarterly EPS Estimates (USD)|Olema Pharmaceuticals inc Quarterly Revenue Estimates (USD)|Olema Pharmaceuticals inc Quarterly EPS Surprise|Olema Pharmaceuticals inc Quarterly Revenue Surprise|Olema Pharmaceuticals inc Quarterly Actual EPS (USD)|Olema Pharmaceuticals inc Quarterly Actual Revenue (USD)|Olema Pharmaceuticals inc Revenue Estimates for Current Fiscal Year (USD)|Olema Pharmaceuticals inc Revenue Estimates for Next Fiscal Year (USD)|Olema Pharmaceuticals inc Price Target (USD)|Olema Pharmaceuticals inc Consensus Recommendation|Olema Pharmaceuticals inc Price Target Num Estimates|Olema Pharmaceuticals inc EPS Estimates for Current Fiscal Year (USD)|Olema Pharmaceuticals inc EPS Estimates for Next Fiscal Year (USD)|Olema Pharmaceuticals inc Research and Development Expense (Quarterly) (USD)|Olema Pharmaceuticals inc Reconciled Depreciation (Quarterly) (USD)|Olema Pharmaceuticals inc Non-Operating Interest Expense (Quarterly) (USD)|Olema Pharmaceuticals inc Land and Improvements (Quarterly) (USD)|Olema Pharmaceuticals inc Buildings and Improvements (Quarterly) (USD)|Olema Pharmaceuticals inc Other Properties (Quarterly) (USD)|Olema Pharmaceuticals inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0301|OLMA|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0301|OLMA|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0301|OLMA|5|127.8|127.8||127.8||127.8|127.8|127.8||127.8|127.8||||1.44755244755||||1.45222929936|||1.45222929936||15.25||127.8|127.8|||31|31|||91.2857142857|45|91.2857142857|91.2857142857|32.1818181818|91.25|127.8|||91.2857142857||||91.25|||||91.2857142857|91.2857142857|91.2857142857|1.45222929936|1.45222929936|1.45222929936|1.43859649123|1.46774193548|15.25|||||91.25|91.25|91||91|91|33.1818181818|40.5555555556|22.8125|10.6486486486|22.8125|21.0588235294|23.8666666667|91.2857142857|91.2857142857|91.2857142857|||91.25|91.25||
new_0222_0301|OLMA|6|5|5||5||5|5|5||5|5||||286||||314|||314||28||5|5|||1|2|||7|1|7|7|11|4|5|||7||||4|||||7|7|7|314|314|314|285|62|28|||||8|8|3||3|3|11|9|16|37|16|17|15|7|7|7|||4|4||
new_0222_0301|OLMA|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0301|OLMA|201912|0.103|0.068||0.026||10.726|1.378|9.348||-10.594|-10.762|||||||||||||||0.935||||||||14.0986||-0.0721|0.107|||37.5197|||-0.0721|||||||||-1.017|-1.017|||||||||||||||||||||||||0.91|0.003|||||||
new_0222_0301|OLMA|202003||||||||||||||||||||||||||||||||||14.0986||-0.1201|0.248||||||-0.1201|||||||||-1.693|-1.693|-0.65||||||||||||||||||||||||0.795|0.003|0.653||||||
new_0222_0301|OLMA|202006||||||||||||||||||||||||||||||||||14.0986||-0.174|0.539||||||-0.174|||||||||-2.453|-2.453|0.033||||||||||||||||||||||||1.947|0.002|||||||
new_0222_0301|OLMA|202009|129.087|127.824||0.024||5.273|5.273|||125.41|-22.963||||||||16.3357|||||1.0918||0.097|0.003||||||25.7919|37.5197|22|-0.2589|3.195|40.1697|-2.289|39.3082|||-0.2091||||-13.007|||||-7.844|-7.844|0.023|51|51|1920.8307|||438563||||||||||||||||||4.673|0.002||||0.088|0.023||
new_0222_0301|OLMA|202012|342.137|338.549||0.075||4.585|4.585|||338.137|-33.094||||-77.8732||||5.5893|||||1.8086||1.361|0.003|||||||39.3082|37|-0.5|3.842|39.3082||39.3082|||-0.5||||-22.121|||||-10.131|-10.131|0.001|48.08|48.08|1551.3893|87569.1333||710914|||||-0.155||-222.5806||-0.5||||60.6667|1.25|3|-1.161|-1.2059|6.289|0.004||||||42.45|39.92
new_0222_0301|OLMA|202103|330.265|326.968||0.526||5.277|5.277|||326.024|-48.433||||-34.3521||||4.0881|||||2.1434||0.49|0.003|||||||39.3258||-0.39|4.758|40.1697||40.1697|||-0.39||||-35.767|||||-15.339|-15.339|0.111|33.18|33.18|1005.8626|226091.9||860988|||||-0.2668||-46.1495||-0.39||||61.6667|1.25|3|-1.2142|-2.11|10.692|0.009||||0.537|0.059|28.05|27.96
new_0222_0301|OLMA|202106|320.854|318.144||0.866||8.146|8.146|||314.084|-64.839||||-21.107||||3.5235|||||5.7068||0.452|0.003|||||||39.4153||-0.42|4.612|39.5526||39.5526|||-0.42||||-49.72|||||-16.406|-16.406|0.117|27.98|27.98|788.5377|280866.2667||2257189|||||-0.3831||-9.6262||-0.42||||55.75|1.2|4|-1.704|-2.734|11.91|0.031||||0.909|0.059|23.48|29.92
new_0222_0301|OLMA|202109|308.28|305.954||0.975||8.901|8.901|||300.894|-82.552||||-18.7418||||3.6346|||||6.0811||0.373|0.003||||1.7402|||39.6077||-0.45|5.239|39.6813||39.6813|||-0.45||||-59.589|||||-17.713|-17.713|0.105|27.56|27.56|787.6626|364130.2667|-82.8431|2413054|||||-0.4309||-4.4447||-0.45||||55.75|1.2|4|-1.6168|-2.3085|12.523|0.05||||1.067|0.059|27|8.75
new_0222_0301|OLMA|202112|||||||||||||||-1.6927||||1.2532|||||9.5204||||||1|1.9879||||||||||||||||||||||||9.36|9.36|71.1379|1317534.5667|-80.5324|3835551|||||-0.4625||||||||46.25|1.2|4|-1.7125|-2.4867||||||||6.43|4.5
new_0222_0301|OLMA|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.56|||||||||||||||||||||
new_0222_0301|OLMA|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.615|||||||||||||||||||||
new_0222_0301|OLMA|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.675|||||||||||||||||||||
new_0222_0301|OLMA|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.805|||||||||||||||||||||